Tirzepatide Research Overview: Dual GIP/GLP-1 Receptor Agonist
Tirzepatide is a synthetic dual agonist of the GIP and GLP-1 receptors with strong phase 3 evidence for type 2 diabetes and obesity. This guide covers its pharmacology, the evidence base, and how community use diverges from labeled protocols.
Sections
Chemical Structure and Pharmacology
Mechanisms Studied in Research
Ready to explore our peptides?
Browse our full range of research-grade peptides with fast EU shipping.
Key Research Applications
Community Use vs Evidence Base
Storage and Regulatory Status
Stay up to date with peptide research
Get the latest research findings, product updates, and exclusive offers delivered to your inbox.
Ready to get started?
Browse our full range of research-grade peptides with fast EU shipping.